{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:55:06Z","timestamp":1792234506143,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40119-022-00269-3","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T07:02:47Z","timestamp":1655967767000},"page":"337-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist"],"prefix":"10.1007","volume":"11","author":[{"given":"Srikanth","family":"Palanisamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Funes Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara I.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"issue":"1","key":"269_CR1","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Barfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340.","journal-title":"J Endocrinol"},{"issue":"23","key":"269_CR2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345(23):1689\u201397.","journal-title":"N Engl J Med"},{"issue":"16","key":"269_CR3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810\u201352.","journal-title":"Circulation"},{"issue":"8","key":"269_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23(8):628\u201351.","journal-title":"J Card Fail"},{"key":"269_CR5","first-page":"CD007004","volume":"4","author":"D Bolignano","year":"2014","unstructured":"Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"269_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AH, Fujita T, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127.","journal-title":"BMC Nephrol"},{"issue":"3S","key":"269_CR7","first-page":"S1","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1\u201387.","journal-title":"Kidney Int"},{"issue":"1","key":"269_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"31","key":"269_CR9","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"key":"269_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","volume":"27","author":"J Yang","year":"2016","unstructured":"Yang J, Young MJ. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol. 2016;27:78\u201385.","journal-title":"Curr Opin Pharmacol"},{"issue":"36","key":"269_CR11","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L, Le Billan F, Kolkhof P, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36):21876\u201389.","journal-title":"J Biol Chem"},{"issue":"39","key":"269_CR12","doi-asserted-by":"publisher","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","volume":"285","author":"J Fagart","year":"2010","unstructured":"Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932\u201340.","journal-title":"J Biol Chem"},{"issue":"12","key":"269_CR13","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/emboj\/17.12.3317","volume":"17","author":"J Fagart","year":"1998","unstructured":"Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, Rafestin-Oblin ME. Antagonism in the human mineralocorticoid receptor. EMBO J. 1998;17(12):3317\u201325.","journal-title":"EMBO J"},{"issue":"10","key":"269_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","volume":"31","author":"A Tomaschitz","year":"2010","unstructured":"Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31(10):1237\u201347.","journal-title":"Eur Heart J"},{"issue":"8","key":"269_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"269_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00424-014-1658-0","volume":"467","author":"Funder JW","year":"2015","unstructured":"Funder JW. Primary aldosteronism and salt. Pflugers Arch. 2015;467(3):587\u201394.","journal-title":"Pflugers Arch"},{"issue":"18","key":"269_CR17","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1161\/01.CIR.0000127949.05756.9D","volume":"109","author":"S Keidar","year":"2004","unstructured":"Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109(18):2213\u201320.","journal-title":"Circulation"},{"issue":"4","key":"269_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1210\/en.2006-1157","volume":"148","author":"Y Hirono","year":"2007","unstructured":"Hirono Y, Yoshimoto T, Suzuki N, et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology. 2007;148(4):1688\u201396.","journal-title":"Endocrinology"},{"issue":"9","key":"269_CR19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1096\/fj.05-4642fje","volume":"20","author":"S Johar","year":"2006","unstructured":"Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006;20(9):1546\u20138.","journal-title":"FASEB J"},{"issue":"8","key":"269_CR20","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1210\/en.2006-1691","volume":"148","author":"S Stas","year":"2007","unstructured":"Stas S, Whaley-Connell A, Habibi J, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology. 2007;148(8):3773\u201380.","journal-title":"Endocrinology"},{"issue":"2","key":"269_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","volume":"39","author":"J Bauersachs","year":"2002","unstructured":"Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39(2):351\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"269_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/01.HYP.0000226054.53527.bb","volume":"48","author":"D Nagata","year":"2006","unstructured":"Nagata D, Takahashi M, Sawai K, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006;48(1):165\u201371.","journal-title":"Hypertension"},{"issue":"2","key":"269_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm1545","volume":"13","author":"JA Leopold","year":"2007","unstructured":"Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13(2):189\u201397.","journal-title":"Nat Med"},{"issue":"6","key":"269_CR24","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120(6):893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"269_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3181\/00379727-104-25782","volume":"104","author":"H Selye","year":"1960","unstructured":"Selye H. Protection by a steroid-spirolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med. 1960;104:212\u20133.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"7","key":"269_CR26","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1210\/en.2004-0005","volume":"145","author":"M Young","year":"2004","unstructured":"Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone\/salt-treated rats. Endocrinology. 2004;145(7):3153\u20137.","journal-title":"Endocrinology"},{"issue":"23","key":"269_CR27","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106(23):2967\u201372.","journal-title":"Circulation"},{"issue":"5","key":"269_CR28","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283(5):H1802\u201310.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"269_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","volume":"168","author":"D Lavall","year":"2019","unstructured":"Lavall D, Jacobs N, Mahfoud F, Kolkhof P, Bohm M, Laufs U. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem Pharmacol. 2019;168:173\u201383.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"269_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","volume":"67","author":"J Grune","year":"2016","unstructured":"Grune J, Benz V, Brix S, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67(5):402\u201311.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"269_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71(4):599\u2013608.","journal-title":"Hypertension"},{"issue":"2","key":"269_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48(2):232\u20138.","journal-title":"Hypertension"},{"issue":"22","key":"269_CR33","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"LA Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295(22):2638\u201345.","journal-title":"JAMA"},{"issue":"2","key":"269_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49(2):355\u201364.","journal-title":"Hypertension"},{"issue":"4","key":"269_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","volume":"45","author":"A Nishiyama","year":"2005","unstructured":"Nishiyama A, Yao L, Fan Y, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005;45(4):710\u20136.","journal-title":"Hypertension"},{"issue":"4","key":"269_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","volume":"43","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats. Hypertension. 2004;43(4):841\u20138.","journal-title":"Hypertension"},{"issue":"1","key":"269_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000335079","volume":"35","author":"AT Whaley-Connell","year":"2012","unstructured":"Whaley-Connell AT, Habibi J, Nistala R, et al. Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR\/S6K1 pathway. Am J Nephrol. 2012;35(1):90\u2013100.","journal-title":"Am J Nephrol"},{"issue":"5","key":"269_CR38","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63(5):1791\u2013800.","journal-title":"Kidney Int"},{"issue":"9","key":"269_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184888","volume":"12","author":"J Dutzmann","year":"2017","unstructured":"Dutzmann J, Musmann RJ, Haertle M, et al. The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE. 2017;12(9): e0184888.","journal-title":"PLoS ONE"},{"key":"269_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","volume":"9","author":"R Gonzalez-Blazquez","year":"2018","unstructured":"Gonzalez-Blazquez R, Somoza B, Gil-Ortega M, et al. Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front Pharmacol. 2018;9:1131.","journal-title":"Front Pharmacol"},{"issue":"10","key":"269_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"14","key":"269_CR42","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"269_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"15","key":"269_CR44","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"4","key":"269_CR45","first-page":"357","volume":"2013","author":"AM Elguindy","year":"2013","unstructured":"Elguindy AM. TOPCAT misses its primary endpoint: should spironolactone be abandoned in HFpEF? Glob Cardiol Sci Pract. 2013;2013(4):357\u201360.","journal-title":"Glob Cardiol Sci Pract"},{"issue":"12","key":"269_CR46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"12","key":"269_CR47","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"269_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41(1):64\u20138.","journal-title":"Hypertension"},{"issue":"11","key":"269_CR49","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedt","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47(11):1936\u20139.","journal-title":"Diabetologia"},{"issue":"6","key":"269_CR50","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68(6):2829\u201336.","journal-title":"Kidney Int"},{"issue":"11","key":"269_CR51","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type\u00a02 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24(11):2285\u201392.","journal-title":"J Hypertens"},{"issue":"5","key":"269_CR52","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type\u00a02 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"269_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2020.08.005","volume":"47","author":"NH Brandt-Jacobsen","year":"2021","unstructured":"Brandt-Jacobsen NH, Johansen ML, Rasmussen J, et al. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type\u00a02 diabetes and high cardiovascular risk: data from the MIRAD trial. Diabetes Metab. 2021;47(4): 101190.","journal-title":"Diabetes Metab"},{"issue":"9","key":"269_CR54","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394.","journal-title":"JAMA"},{"issue":"27","key":"269_CR55","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of finerenone vs eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314.","journal-title":"Eur Heart J"},{"issue":"24","key":"269_CR56","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type\u00a02 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"23","key":"269_CR57","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"6","key":"269_CR58","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type\u00a02 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"key":"269_CR59","unstructured":"Food and Drug Administration. FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type\u00a02 diabetes [press release]. Food and Drug Adminstration, 2021."},{"key":"269_CR60","unstructured":"ClinicalTrials.gov. A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease (FIND-CKD). US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05047263?term=finerenone&draw=2&rank=8. Accessed 28 Feb 2022."},{"issue":"11","key":"269_CR61","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1515\/cclm-2018-0245","volume":"56","author":"A Gay","year":"2018","unstructured":"Gay A. Letter to the Editor relative to Clin Chem Lab Med 2018;56(3):360\u2013372. Clin Chem Lab Med. 2018;56(11):251\u20132.","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"269_CR62","first-page":"1182","volume":"382","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, McMurray JJV, PARAGON-HF Steering Committee and Investigators. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. Reply. N Engl J Med. 2020;382(12):1182\u20133.","journal-title":"N Engl J Med"},{"issue":"16","key":"269_CR63","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"269_CR64","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF). US National Library of Medicine. 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435626?term=finerenone&draw=2&rank=7. Accessed 28 Feb 2022."},{"key":"269_CR65","unstructured":"ClinicalTrials.gov. A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alone in adult participants with long-term kidney disease (chronic kidney disease) and type\u00a02 diabetes (CONFIDENCE). 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05254002?term=finerenone&draw=2&rank=1. Accessed 28 Feb 2022."}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00269-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-022-00269-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-022-00269-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T11:05:21Z","timestamp":1660647921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-022-00269-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["269"],"URL":"https:\/\/doi.org\/10.1007\/s40119-022-00269-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}